Boyd Hehn, MD
Pulmonary Disease · Philadelphia, PANPI 1134212129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,635 of the $156,787 with a category attached, or 88.4%. GSK accounts for 64.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $44,632 and has fallen 55.1% since, to $20,024 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $699.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$101K
- AstraZeneca$42K
- Johnson & Johnson$7K
- Covidien LP$3K
- Pulmonx Corporation$2K
- Grifols USA, LLC$285
- plus $677 from 9 others
Across 8 payments — averaging $9046.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$72K
What the payments were for
- Consulting fees$8,9676%
- Speaking & faculty fees$138,63588%
- Travel & lodging$2,9212%
- Food & beverage$6,1894%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 91 | $101,165 |
| AstraZeneca | 53 | $42,289 |
| Johnson & Johnson | 11 | $7,457 |
| Covidien LP | 7 | $3,056 |
| Pulmonx Corporation | 33 | $1,857 |
| Grifols USA, LLC | 12 | $285 |
| Intuitive Surgical | 3 | $210 |
| Astrazeneca UK Limited | 1 | $113 |
| Insmed, Inc. | 4 | $91 |
| Galvanize Therapeutics, Inc | 1 | $79 |
| Boston Scientific | 3 | $77 |
| Inspire Medical Systems, Inc. | 2 | $53 |
| Pfizer | 1 | $26 |
| Sanofi | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$41,064
- TRELEGY ELLIPTA$40,809
- AREXVY$12,025
- ANORO ELLIPTA$10,924
- Monarch Platform$7,335
- superDimension$3,014
- ZEPHYR ENDOBRONCHIAL VALVE$881
- CHARTIS CATHETER$481
- ZEPHYR DELIVERY CATHETER$481
- PULMONX CHARTIS TABLET CONSOLE$481
- Da Vinci Surgical System$154
- Pulmonx Endobronchial Valve EBV$106
How this compares
$156,787 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 35 | $806,243 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 531 | $443,664 |
| Ambrisentan | 69 | $217,118 |
| Orenitram ErTreprostinil Diolamine | 22 | $146,816 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $110,669 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 117 | $70,673 |
| Spiriva RespimatTiotropium Bromide | 53 | $47,799 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 73 | $42,118 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $40,087 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $36,183 |
| Spiriva HandihalerTiotropium Bromide | 42 | $20,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 492 | $17,603 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $15,830 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $14,386 |
| Bosentan | 13 | $13,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $101,165 | $565,613758 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $42,289 | $130,285192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
- Jeffrey ThompsonPhiladelphia$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.